Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy

Urology
Hiroshi KitamuraTaiji Tsukamoto

Abstract

To assess the expression of survivin in transitional cell carcinoma of the bladder and to study whether survivin is a transitional cell carcinoma-specific antigen that could be a target for immunotherapy. Survivin, an inhibitor of apoptosis family member, has been reported to be expressed in various cancers but not in normal adult tissues. Immunohistochemical staining for survivin and human leukocyte antigen (HLA) class I was performed on specimens from 88 patients who underwent transurethral resection and radical cystectomy. To determine whether survivin was recognized as a tumor antigen by the host immune system, we assessed anti-survivin antibodies in the sera of 52 patients and 18 healthy volunteers with an enzyme-linked immunosorbent assay using recombinant survivin. Survivin and HLA class I were expressed in 77 (87.5%) and 59 (67.0%) of the 88 bladder cancer specimens, respectively, and 56 (63.6%) expressed both survivin and HLA class I. The absorbance values of anti-survivin antibodies in patients with bladder cancer were significantly greater than those in the healthy volunteers. A relationship was found between the level of serum anti-survivin antibodies and the staining intensity of survivin in the specimen. Survivin ...Continue Reading

References

Aug 1, 1997·Nature Medicine·G AmbrosiniD C Altieri
Feb 17, 1999·Genes & Development·Q L Deveraux, J C Reed
Aug 7, 1999·The New England Journal of Medicine·H S SwanaD C Altieri
Aug 21, 2001·Journal of Insurance Medicine·M Moore
Apr 3, 2002·Seminars in Cancer Biology·Barbara SeligerSoldano Ferrone
Jun 6, 2002·Journal of the National Cancer Institute·Giorgio ParmianiAndrea Anichini
Jan 10, 2004·The Journal of Urology·Shahrokh F ShariatSeth P Lerner
Jan 10, 2004·The Journal of Urology·Kent G KrejciEugene D Kwon
May 13, 2004·Journal of Cancer Research and Clinical Oncology·Haidong WangGen Ge

❮ Previous
Next ❯

Citations

Dec 10, 2013·Actas urologicas españolas·R CarreteroJ M Cózar
May 16, 2009·Cancer Science·Yoshihiko HirohashiNoriyuki Sato
Apr 9, 2009·Pathology International·Noriyuki SatoToshihiko Torigoe
Jul 22, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Xue-Quan CaoMei-Fu Gan
Jan 1, 2011·Cancers·Hiroshi Kitamura, Taiji Tsukamoto
Jul 3, 2013·Cancer Control : Journal of the Moffitt Cancer Center·Shilpa Gupta, Amit Mahipal
Aug 11, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hiroshi KitamuraTaiji Tsukamoto
Mar 27, 2021·Frontiers in Immunology·Karthik DhatchinamoorthyKenneth L Rock

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.